Pilot Study on the Use of iENTER, iCONSENT and iPARTICIPATE E-tools
NCT06317961 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2024-03-19
Summary
Precision oncology is the future of fighting cancer. Cancer Core Europe (CCE) developed a precision medicine trial, i.e. the Basket of Basket (BoB) study, to provide personalised treatment to a large number of patients by incorporating a molecular profiling platform. The EU-funded CCE\_DART project, developed within the CCE Consortium, is aimed at improving efficiency and transform platform trials into data-rich translational research programmes. Within the CCE\_DART project working area D "Patient involvement through information and partnership" three interconnected web e-tools were developed aimed at promoting patient information, recruitment, and involvement as well as facilitating adherence to the CCE BoB trial: 1) iENTER: informative web site addressed to potential BoB trial participants, their caregivers, patients' advocates, and the public; 2) iCONSENT: web app for remote management of the informed consent process in the CCE BoB trial.3) iPARTICIPATE: web app allowing remote access to BoB trial patients trial visits calendar, medications list and posology, to upload documents and download reports, messaging between patients and clinical staff. The main objective of this study is to carry out field testing and assess usability of the e-tools iENTER, iCONSENT and iPARTICIPATE. The study is also addressed at collecting patients' suggestions for improvements of the e-tools.
Conditions
Sponsors & Collaborators
-
Vall d'Hebron Institute of Oncology
collaborator OTHER -
The Netherlands Cancer Institute
collaborator OTHER -
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-05
- Primary Completion
- 2025-01-31
- Completion
- 2025-01-31
Countries
- Italy
Study Locations
More Related Trials
-
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965 ·Status: RECRUITING ·Phase: PHASE3
-
Sequential Combination Therapy in Bladder Cancer
NCT03790384 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Screening Using IMD in Bladder Cancer
NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT03628716 ·Status: COMPLETED ·Phase: PHASE2
-
Prognostic Performance of a Chemogram in Patients With Bladder Cancer.
NCT06403202 ·Status: RECRUITING
-
Evaluation of a Patient-Reported Symptom Index for NMIBC
NCT03091764 ·Status: COMPLETED
-
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
NCT06245603 ·Status: RECRUITING ·Phase: NA
-
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
NCT06679920 ·Status: RECRUITING ·Phase: NA
-
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
NCT03768570 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820 ·Status: RECRUITING ·Phase: PHASE3
-
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
NCT02716961 ·Status: UNKNOWN ·Phase: NA
-
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
NCT00014144 ·Status: COMPLETED ·Phase: PHASE2
-
Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer
NCT06009510 ·Status: NOT_YET_RECRUITING
-
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00191711 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
NCT06766266 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine Cytology
NCT01551342 ·Status: UNKNOWN
-
Cost-Effectiveness in Bladder Cancer
NCT00126958 ·Status: UNKNOWN
-
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
NCT02625961 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer
NCT02826564 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Tumour Focused Radiotherapy for Bladder Cancer
NCT02447549 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cystoscopic Imaging Collection and Enhancement pROject
NCT02427321 ·Status: COMPLETED
-
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
NCT02178241 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
NCT01625260 ·Status: TERMINATED ·Phase: PHASE1/PHASE2